INDIVIOR PLC/S (INVVY) Downgraded to Sell at Zacks Investment Research
Zacks Investment Research downgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a hold rating to a sell rating in a report released on Tuesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
A number of other research firms also recently weighed in on INVVY. Citigroup reaffirmed a neutral rating on shares of INDIVIOR PLC/S in a research note on Thursday, May 31st. ValuEngine downgraded INDIVIOR PLC/S from a buy rating to a hold rating in a research note on Saturday, June 16th.
INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its quarterly earnings data on Thursday, July 26th. The company reported $0.45 earnings per share (EPS) for the quarter. The business had revenue of $268.00 million during the quarter. sell-side analysts predict that INDIVIOR PLC/S will post 1.74 earnings per share for the current fiscal year.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Article: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.